The mechanism of dasatinib in the treatment of chronic myelogenous leukemia

The specific mechanism behind dasatinib (Dasatinib) treatment of chronic myelogenous leukemia is unclear. It may induce immune modifications that reveal a more diverse T cell population compared with imatinib; this could be demonstrated by a higher proportion of effector CD4+ T cells in patients with chronic myelogenous leukemia treated with dasatinib.

After oral administration, dasatinib is rapidly absorbed and reaches peak plasma concentration within 0.5-3 hours, and its solubility depends on pH. Increases in dendritic cells, cytotoxic T cells, and natural killer cells have been reported in peripheral blood samples in cases treated with dasatinib, and one study demonstrated that increasing serum interleukin-10 levels through activated dendritic cells modulates the chemotherapeutic activity of dasatinib. Based on previous findings, dasatinib treatment may provide clinical benefit in inflammatory diseases. However, the magnitude of the immunomodulatory effect may also be affected by some clinically relevant side effects, such as pleural effusion and thrombocytopenia following dasatinib treatment.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).